kol breakfast new indic zilucoplan
start
kol discuss use zilucoplan imnm rare autoimmun muscl diseas
approv therapi view underscor drug therapeut
potenti elig imnm patient us new indic could
us market opportun zilucoplan gmg imnm track start
continu view rarx compel smid-cap opportun biotech
approv therapi imnm knowledg anyth
develop rarx estim elig patient us -- market opportun
rarx host kol breakfast immune-medi necrot myopathi imnm
dr andrew mammen nih co-found john hopkin myositi center
imnm character muscl inflamm weak skelet muscl statin
may trigger accord recent find distinct auto-antibodi present
case anti-sign recognit particl anti-srp younger/femal anti-
pathogen auto-antibodi requir complement system imnm patient
auto-antibodi high level creatin kinas ck biomark muscl injuri
iu/l vs normal iu/l deposit complement membran attack complex
muscl fiber surfac per rarx elig patient
us/eu/japan despit current treatment steroid immuno-suppress ivig
rituxan patient severe/progress condit anoth third
incomplet respons treatment ck level iu/l weak muscl
random double-blind trial zilucoplanin anti-hmgcr/-srp imnmon track
data kol seesnot ck reductionwithin week zilucoplanstart
ind clear random placebo-control double-blind
studi key imnm clinic center week follow open-label extens
primari endpoint chang ck level baselin week functional-
assess secondari endpoint kol note reduct ck level
baselin would signific effect muscl strength compar steroids/
immuno-suppress take week lower ck level significantli kol/
rarx expect ck reduct week zilucoplan start function improv
lag month time muscl recoveri per kol thu eight week
random part kol see signific reduct ck level posit
trend function assess kol expect new imnm patient per month
patient current care institut anti-hmgcr/anti-
srp meet entri criteria alongsid approv therapi mean rapid
patient enrol key imnm center
rais pt addit imnm indic zilucoplan probability-
adjust assum launch peak us sale
given complement-medi imnm posit auto-antibodi think zilucoplan
work imnm poc clinic data yet assign conserv
probabl success revis pt compris fair valu
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
zilucoplan gmg probability-adjust zilucoplan imnm
probability-adjust zilucoplan pnh probability-adjust
collaboration/technolog valu use annual discount rate
pleas see import disclosur inform page report
cash suffici
lead candid zilucoplan inhibitor enter
gener myasthenia gravi gmg
immune-medi necrot myopathi imnm
pt base npv analysi rarx
success zilucoplan gmg pnh imnm
gener addit drug candid leverag
zilucoplan success gmg imnm sum-
of-the-part analysi peg pt rarx share
failur zilucoplan gmg imnm
zilucoplan fail gmg imnm see pt
rarx lead drug candid clinic develop
daili subcutaneous/sc inhibitor zilucoplan
complement-medi diseas pnh gmg
soliris/ultomiri pnh ahu gmg nmo expect
gener sale zilucoplan
success develop abl captur
soliris/ultomiri share see signific potenti
upsid rarx share current valuat
initi zilucoplan gmg
initi zilucoplan imnm data
clinic studi extend releas xr formul
weekli less frequent dose zilucoplan
oral inhibitor start
pleas see import disclosur inform page report
compani report jefferi
pleas see import disclosur inform page report
productdescriptionindicationstatusmarket rightspat expirygener myasthenia gravi gmg singl start primari endpoint mg-adl data potenti ethnobridg studi japan underway multi-dos cohort single-dos cohort complet necrot myopathi start data ind clear random double-blind placebo-control multi-cent studi primari endpoint chang creatin kinas ck level baselin week option enter ole studyparoxysm nocturn hemoglobinuria pnh postpon single-arm prior start transfusion-depend tx-naiv pt mg/kg support studi mg/kg transfusion-independ pt plan use extend formul weekli less frequent sc hemolyt urem syndrom ahu lupu nephriti ln data show similar pk profil pt sever renal impair healthi volunt reduct zilucoplan plasma concentr period weekli sc inhibitor zilucoplan preclin data peptid congress clinic studi start higher volum weekly/less frequent sc vs daili second oral inhibitorpnh gmg ln diseasespreclin clinic studi start vs prior clinic candid select amd/geograph atrophi glomerulonephr dens deposit diseas inhibitorautoimmune/ diseasepreclin discoveri stage rarxpartn programsmerck collaborationundisclos non-compl cv targetcardiovascular diseasepreclin lead oral peptid class select lactat dehydrogenaseproprietari programsfactor inhibitorfactor inhibitor intravitr deliveri ocular indic rarxpreclin clinic candid select subcutan synthet macrocycl peptid inhibitor complement compon patent applic famili relat inhibitor method use expiri grant fda eu orphan drug design receiv equiti research
compani report jefferi
pleas see import disclosur inform page report
zilucoplan gmg us sale growth ex-u sale partner- growth imnmu sale growth ex-u sale partner- growth pnhu sales- growth ex-u salesbi partner- growth total growth good sold gross growth growth expens loss oper growth incom expens loss benefit incom tax incom loss extinguish redeem convert prefer sharesnet incom loss attribut common sharehold forma ep lp common sharehold basic forma ep lp common sharehold dilut lp common sharehold basic dilut -- -- -- -- -- forma share forma share basic dilut -- -- -- -- -- cash equival pharmaceuti rarx incom statement thousand except per share equiti research
ra incorpor locat cambridg clinical-stag biopharmaceut compani
proprietari peptid chemistri drug discoveri platform enabl identifi produc new therapeut complement-medi
diseas rarx lead candid zilucoplan subcutan administ inhibitor enter phase trial
paroxysm nocturn hemoglobinuria pnh gener myasthenia gravi gmg addit preclin candid
includ factor inhibitor oral inhibitor inhibitor util technolog platform rarx establish
collabor licens agreement merck identifi oral avail non-compl target cyclic peptid
pt base npv analysi zilucoplan gmg imnm pnh technolog value/merck collabor risk includ
eun yang ph certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
alexandra heller certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
suji jeong ph certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
